DeferiproneA Review of its Clinical Potential in Iron Overload in β-Thalassaemia Major and Other Transfusion-Dependent Diseases

被引:0
作者
Julia A. Barman Balfour
Rachel H. Foster
机构
[1] Adis International Limited,
来源
Drugs | 1999年 / 58卷
关键词
Adis International Limited; Serum Ferritin; Iron Overload; Deferoxamine; Serum Ferritin Level;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:553 / 578
页数:25
相关论文
共 333 条
[1]  
Olivieri NF(1997)Iron-chelating therapy and the treatment of thalassemia Blood 89 739-61
[2]  
Brittenham GM(1997)A risk-benefit assessment of iron-chelation therapy Drug Saf 17 407-21
[3]  
Porter JB(1997)Iron chelation therapy J Intern Med 740 37-41
[4]  
Hoffbrand AV(1996)Results of long-term iron-chelating therapy Acta Haematol 95 26-36
[5]  
Wonke B(1995)Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination Semin Hematol 32 269-79
[6]  
Gabutti V(1995)Chelation therapy in β-thalassemia: the benefits and limitations of desferrioxamine Semin Hematol 32 304-12
[7]  
Piga A(1987)Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine J Clin Pathol 40 1353-9
[8]  
Kattamis CA(1989)The toxic effects of desferrioxamine Baillieres Clin Haematol 2 459-74
[9]  
Kattamis AC(1996)Oral iron chelation Semin Hematol 33 1-8
[10]  
Giardina PJ(1992)Aluminium removal: short- and long-term preliminary results with L1 in rats Drugs Today 28 177-82